Understanding Adenomyosis: Causes, Symptoms and Treatment Options

Speciality: Obstetrics and Gynecology


Speaker:

Dr. Asha R.Rao | MD, DGO, FICOG, Infertility Specialist, Obstetrician, Gynecologist

Prof. S Shantha Kumari | MD, DNB, FICOG, FRCPI (Ireland) FRCOG (UK), President FOGSI 2021-2023, Honorary Treasurer FIGO 2021-2023

Dr. Madhuri Patel | MD, DGO, FICOG, Hon. Clinical Associate

Dr. Nandita P Palshetkar | MBBS, MD - Obstetrics & Gynaecology, FCPS - Mid. & Gynae, Fellow of Indian College of Obstetrics and Gynecology (FICOG), Infertility Specialist, Laparoscopic Surgeon (Obs & Gyn)

Description:

A warm welcome to all the medical professionals in this interesting session of management of enigmatic adenomyosis. In this webinar, the speakers, Dr. Asha R.Rao, Prof. S Shantha Kumari, Dr. Madhuri Patel, Dr. Nandita P Palshetkar and panel have shared the important facts associated with the management of enigmatic adenomyosis. 

Adenomyosis is a gynecologic condition that causes the endometrial tissue in the lining of the uterus to grow into the muscular wall of the uterus causing enlargement of the uterus. Basically these are not harmful but can lead to very heavy menstrual bleeding along with severe pain, thereby, affecting regular lifestyle.

Adenomyosis is traditionally considered as an enigmatic disease. It is a uterine disease that affects many women of reproductive age and is a contributing factor for pelvic pain, heavy menstrual bleeding (HMB), and subfertility. 

Therefore,  you are going to have an overall knowledge on adenomyosis management using advanced treatment approaches such as IVF. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot